peopleInnovationCareers RarePipelineCollaborationFinanceAdvance treatment Skip to main contentSkip to navigationSkip to search
Hansa Biopharma
HNSA (, %) SEK
Hansa Biopharma

HMD-301 for diagnosis of Urinary Tract Infection: novel clinical results published

20 Mar 2012, 09:00
Regulatory information
Hansa Medical’s clinical research partners at Skåne University Hospital in Lund have conducted a clinical study demonstrating that the patented diagnostic method HMD-301 is suitable for diagnosis of Urinary Tract Infections in children. The results of the study have been published online by the scientific journal Pediatric Nephrology

Urinary tract infection (UTI) is a common infection diagnosis in children, and efficient diagnosis and treatment is important to avoid serious complications. The published study shows that by quantifying the level of Heparin Binding Protein in urine samples, individuals with UTI could be discerned with sensitivity above 90 % and specificity above 90%. These levels of accuracy are highly competitive in comparison with the commonly used methods for UTI-diagnosis today: Nitrite quantification, White Blood Cell count or Interleukin-6 quantification. The study involved a small group of patients (78 children aged 0-18 years) and further studies are ongoing with a larger group of patients.

”The results from the published study are very promising and make up an additional development opportunity for the patented diagnostic method HMD-301", says Emanuel Björne, CEO of Hansa Medical AB

For further information, please contact:
Hansa Medical AB
Emanuel Björne, CEO
Mobile: 46 707 17 54 77

Hansa Medical is a drug and diagnostics discovery company focused on inflammatory diseases. The company develops innovative biological pharmaceuticals and diagnostic methods both independently and in partnership with large, established companies. At present, the company is primarily undertaking three development projects: IdeS, EndoSand HMD-301. New development projects and product candidates generated through cooperation with medical academic research are continuously evaluated. The main shareholders of Hansa Medical are Bo Håkansson via Farstorps Gård AB, and Bengt Ågerup via NXT2B AB. Hansa Medical is listed on NASDAQ OMX First North, and Remium Nordic AB is the company’s Certified Adviser.